Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$5.17
+$0.14 · +2.78%
InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.
Latest quote
$5.17
+$0.14 · +2.78%
After-hours
$5.02
−$0.15 · -2.90%
Oct 9, 5:14 PM ET
Regular session · ET · Market data may be delayed.
InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.
52-week range
Current $5.17
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
55
Mixed
Risk
68
High Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.
52-week range
Current $5.17
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (ILS) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 270.2M ILS | 238.85M ILS | 355.55M ILS | 388.68M ILS | 219.68M ILS |
| Cost of goods sold | 237.02M ILS | 208.61M ILS | 250.46M ILS | 233.6M ILS | 128.55M ILS |
| Gross profit | 33.18M ILS | 30.23M ILS | 105.1M ILS | 155.08M ILS | 91.13M ILS |
| Research and development | 390K ILS | 414K ILS | 388K ILS | 632K ILS | 1.24M ILS |
| Selling, general, and administrative | 80.41M ILS | 84.63M ILS | 86.24M ILS | 97.32M ILS | 53.46M ILS |
| Operating expenses | 26.45M ILS | 97.44M ILS | 146.66M ILS | 104.46M ILS | 62.95M ILS |
| Interest income | 1.56M ILS | 2.7M ILS | 4.55M ILS | 844K ILS | 130K ILS |
| Interest expense | 19.66M ILS | 20.65M ILS | 24.22M ILS | 14.69M ILS | 5.05M ILS |
| Depreciation and amortization | 17.15M ILS | 15.37M ILS | 13.17M ILS | 11.7M ILS | 7.39M ILS |
| Operating income | 6.73M ILS | −67.21M ILS | −41.57M ILS | 50.63M ILS | 28.19M ILS |
| Net income | −35.71M ILS | −67.8M ILS | −61.96M ILS | 44.82M ILS | 4.69M ILS |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 24, 2026 | 1:5 | — | — |
Stock split | Apr 8, 2021 | 1:4 | — | — |
Effective Aug 24, 2026
1:5
Effective Apr 8, 2021
1:4
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
